According to a recent LinkedIn post from Koios Care, the company plans to participate in the AD/PD conference in Copenhagen from March 17–21, focusing on results from its Q-index study in Parkinson’s Disease. The post highlights that Koios Care intends to showcase methods for capturing meaningful changes in patient functioning in daily life and assessing treatment effectiveness in a longitudinal trial setting.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post suggests that the company is leveraging commercial wearables to detect motor complications in Parkinson’s Disease through continuous, non-invasive monitoring. It indicates that such technology may support personalized medication timing and objective treatment efficacy tracking, potentially positioning Koios Care within the growing market for digital health endpoints and real-world evidence solutions.
As described in the post, applying wearable-based, remote endpoints in clinical trials could lower study costs while meeting regulatory expectations for real-world evidence and patient-relevant outcomes. For investors, this emphasis on clinically meaningful, data-rich monitoring may signal a strategy aimed at partnering with pharmaceutical sponsors and clinical researchers, which could expand Koios Care’s addressable market and enhance its competitive standing in neurology-focused digital health.